Clinical Trial Detail

NCT ID NCT02151084
Title A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors University Health Network, Toronto
Indications

biliary tract cancer

gallbladder carcinoma

Therapies

Cisplatin + Gemcitabine + Selumetinib

Age Groups: adult

No variant requirements are available.